GenVec, Novartis ink clinical trials supply deal
GenVec could receive approximately $13 million over four years after inking an agreement with Novartis through which it will manufacture clinical trial material for up to two lead candidates. The two companies are partnered on clinical programs for hearing loss and balance disorders. GenVec release
Comments